ClinicalTrials.gg
CompletedNCT06654960Updated Jan 7, 2025

Influence of HRS9531 on Pharmacokinetics of Metformin in Healthy Subjects

A Phase 1 interventional study of HRS9531 injection and Metformin Hydrochloride tablets in Type 2 Diabetes, sponsored by Fujian Shengdi Pharmaceutical Co., Ltd.. Completed at 1 site in China. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-01-07.

Sponsored by Fujian Shengdi Pharmaceutical Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years to 45 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing ribupatide in Diabetes Mellitus, Type 2 — 1 open to participants now, 1 under way, 1 of them phase 3. ribupatide · Diabetes Mellitus, Type 2.

Enrollment
11th of 11
20 · median 72
Started
2024
with 5 others
Phase 1
7 of 11
none open now
Registered
9th of 11
by date
Lead sponsor
11 of 11
Fujian Shengdi Pharmaceutical Co., Ltd.

Among the 11 studies testing ribupatide in Diabetes Mellitus, Type 2, this one is the 11th largest by enrollment, is one of 6 that started in 2024, is one of 7 in phase 1, and was the 9th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

1 of the 11 studies testing ribupatide in Diabetes Mellitus, Type 2 is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Where they have run

About ribupatide

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years to 45 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing ribupatide in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the influence of HRS9531 injection on pharmacokinetics of metformin in healthy subjects.

03

Conditions studied

  • Type 2 Diabetes
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Ability to understand the trial procedures and possible adverse events, be able and willing to provide a written ;
  2. Male subjects aged 18-45 years on the date of signing informed consent (inclusive);
  3. Body weight ≥50 kg, (BMI) within the range of 20.0-30.0 kg/m2 (inclusive);
  4. \<6.0%.

Exclusion criteria

Exclusion Criteria:

  1. Chronic or severe medical history of the respiratory system, circulatory system, digestive system, urinary system, blood system, endocrine system, immune system, nervous system, mental system, etc., or those with existing systemic diseases mentioned above, and judged by the investigator to be unsuitable to participate in this study;
  2. Obvious gastric emptying abnormalities or gastrointestinal diseases in the past, or had undergone gastrointestinal surgery (except for gastrointestinal polyps, appendix, and haemorrhoidectomy)
  3. Past history or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2 (MEN2), a history of pancreatitis or symptomatic gallbladder stones;
  4. Surgery within 6 months prior to dosing, planned to undergo surgery during the study period;
  5. Participation in clinical trials of any drug or medical device in the 3 months or 5 half-lives, whichever longer, prior to dosing;
  6. Blood donation history or blood loss ≥400 mL within 3 months or ≥200 mL within 1 month before dosing, or received blood transfusion within 3 months before dosing;
  7. Allergic constitution includes severe drug allergy or history of drug allergy;
  8. surface antigen (HBsAg), antibody, virus antibody (HCVAb), treponema pallidum specific antibody detection, positive;
  9. Abnormal laboratory test results or abnormal examinations considered unsuitable to participate in this trial;
  10. History of hypoglycaemia;
  11. The investigator considers that the subject has any other factors that would make it inappropriate to participate in this study.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Single arm

    Drug: HRS9531 injection · Drug: Metformin Hydrochloride tablets

Interventions

06

What researchers measure

Primary outcomes

  1. Area under the concentration versus time curve (AUC) of metformin from dosing time (0) to tau (dosing interval) (AUCtau) after 3.5 days.

    Time frame: Start of treatment up to 12 hours.

Secondary outcomes

  1. Time to maximum concentration (Tmax) of metformin after 3.5 days of treatment.

    Time frame: Start of Treatment up to 30 hours.

  2. Maximum concentration (Cmax) of metformin after 3.5 days of treatment.

    Time frame: Start of Treatment up to 30 hours.

  3. Area under the concentration versus time curve of metformin from 0 to the time of the last measurable (positive) concentration (AUC0-t) after 3.5 days of treatment.

    Time frame: Start of Treatment up to 30 hours.

  4. Area under the concentration versus time curve of metformin from 0 to infinity (AUC0-inf) after 3.5 days of treatment.

    Time frame: Start of Treatment up to 30 hours.

  5. Terminal half-life (t1/2) of metformin after 3.5 days of treatment.

    Time frame: Start of Treatment up to 30 hours.

  6. Clearance (CL/F) of metformin after 3.5 days of treatment.

    Time frame: Start of Treatment up to 30 hours.

  7. Apparent volume of distribution (VzF) of metformin after 3.5 days of treatment.

    Time frame: Start of Treatment up to 30 hours.

  8. Time to maximum concentration (Tmax) of HRS9531.

    Time frame: Start of Treatment up to 504 hours.

  9. Maximum concentration (Cmax) of HRS9531.

    Time frame: Start of Treatment up to 504 hours.

  10. Area under the concentration versus time curve of HRS9531 from 0 to the time of the last measurable (positive) concentration (AUC0-t).

    Time frame: Start of Treatment up to 30 hours.

  11. Area under the concentration versus time curve of HRS9531 from 0 to infinity (AUC0-inf).

    Time frame: Start of Treatment up to 504 hours.

  12. Terminal half-life (t1/2) of HRS9531.

    Time frame: Start of Treatment up to 504 hours.

  13. Clearance (CL/F) of HRS9531.

    Time frame: Start of Treatment up to 504 hours.

  14. Apparent volume of distribution (VzF) of HRS9531.

    Time frame: Start of Treatment up to 504 hours.

  15. Incidence and severity of adverse events.

    Time frame: Screening period up to 42 days.

07

Study locations

1 site
  • The Second Affiliated Hospital of Anhui Medical University
    Hefei, Anhui 230000, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2024 to primary completion in Dec 2024, 1 month.

Of 453 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 11. This study's 1 month is below that.

Counting every sponsor, half of 515 studies reached it within 6 months; a quarter within 2 and three quarters within 14.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 21, 2024
First posted
Oct 23, 2024
StartActual
Nov 5, 2024
Primary completionActual
Dec 26, 2024
CompletionActual
Dec 26, 2024
Last update
Jan 7, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 7, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06654960
Responsible party
Sponsor
First posted
Oct 23, 2024
Start date
Nov 5, 2024
Primary completion
Dec 26, 2024
Completion
Dec 26, 2024
Last update
Jan 7, 2025

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ribupatide

Start the discussion